8-K current report · filed Nov 5, 2026

JOINT Corp (JYNT) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item 8.01Item EX-99.1Item EX-99.2JYNT overview

Short answer

JOINT Corp (JYNT) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Press release announces JOINT Corp financial results for quarter ended September 30, 2026.

JOINT Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces JOINT Corp financial results for quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed quarterly results and management commentary

Item 7.01 · Regulation FD Disclosure

  • Earnings presentation for fiscal-year 2026 results available on JOINT’s investor-relations website and in Exhibit 99.2
  • Presentation supports the November 5, 2026 earnings call and future analyst and investor discussions
  • Investors should review Exhibit 99.2 for management’s financial results, outlook, and key operating metrics

Item 8.01 · Other Events

  • Board authorized an additional $5.0 million for common-stock repurchases
  • Authorization runs through November 4, 2027, unless exhausted or terminated earlier
  • Repurchases may reduce shares outstanding and support per-share metrics
  • Timing and volume remain discretionary, dependent on market and business conditions

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $13.6M, up 1%, while system-wide sales fell 3.1% and comps remained negative at (1.9%)
  • Continuing-operations net income $1.5M and Adjusted EBITDA $2.3M, versus $290K and $1.4M respectively
  • Texas RD rights reacquired for $8.0M upfront, covering 141 franchised clinics, plus up to $2.0M contingent consideration
  • Five 2026 RD buybacks cover 189 clinics, targeting $3.0M annualized royalty savings, offset by approximately one-third internal costs
  • Guidance reduced: 2026 system-wide sales $508M-$512M and comps (3.5)% to (2.5%), while Adjusted EBITDA remains $12.5M-$13.5M
  • $5.0M new repurchase authorization after $3.8M Q3 buybacks, supporting per-share value but further reducing cash reserves

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $13.6M, up $0.2M, while continuing-operations net income rose to $1.5M from $0.3M
  • Continuing-operations Adjusted EBITDA increased $0.9M to $2.3M, signaling improved profitability from the capital-light model
  • System-wide sales $123.3M, down 3.1%, with comparable sales down 1.9%, though comps improved 90 basis points sequentially
  • 2026 guidance narrowed to system-wide sales $508M-$512M and comp sales down 3.5% to 2.5%; clinic count expected approximately 50 below 2025 year-end
  • Repurchased approximately 461,000 shares for $3.8M in Q3 and authorized an additional $5M, supported by $18.3M unrestricted cash and $20M credit availability

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other JOINT Corp 8-K filings

Get the next JYNT 8-K as it lands

Follow JYNT for push alerts, or ask the research agent what this filing means.